Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enzomenib - Sumitomo Pharma

Next Previous
Drug Profile

Enzomenib - Sumitomo Pharma

Alternative Names: DSP-5336

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Developer Sumitomo Pharma; Sumitomo Pharma America
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Menin inhibitors; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 14 Apr 2025 Sumitomo Pharma establishes CRADA with the National Cancer Institute (NCI) for the development of enzomenib in Cancer
  • 17 Dec 2024 Chemical structure information added.
  • 09 Dec 2024 Efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia and Precursor cell lymphoblastic leukaemia-lymphoma released by Sumitomo Pharma America

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top